Lenalidomida Tecnigen

Lenalidomide, the active ingredient in Lenalidomida Tecnigen, is an immunomodulatory drug (IMiD) presented as an oral tablet for systemic use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q) and mantle cell lymphoma, targeting malignant cell growth and immune modulation.

GNH USA supplies Lenalidomida Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.

- Multiple myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission. - Mantle cell lymphoma: contributes to disease control in patients who have received prior therapies.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Diarrhea - Rash - Constipation

Serious or Rare Side Effects: - Venous thromboembolism - Secondary primary malignancies - Severe neutropenia - Severe infections - Hepatotoxicity - Tumor lysis syndrome

When prescribing Lenalidomida Tecnigen, clinicians should observe several safety measures to minimize risk.

- Pregnancy contraindication: drug is teratogenic (Category X) and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Renal/hepatic function: adjust dose in patients with impaired clearance. - Drug interaction vigilance: avoid concomitant use with strong CYP3A4 inducers. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Lenalidomide interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma concentrations and therapeutic effect. - Live vaccines: concurrent use can increase risk of severe infection. - Anticoagulants (warfarin): may increase bleeding risk when combined with lenalidomide‑induced thrombocytopenia.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (aspirin, clopidogrel): monitor platelet counts and bleeding signs. - P‑glycoprotein inhibitors (e.g., verapamil): may increase lenalidomide exposure. - Non‑live vaccines: timing should be coordinated with treatment cycles.